Impact of RANGAP1 SUMOylation on Smad4 nuclear export by bioinformatic analysis and cell assays

Authors

  • Feng Zhang Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China
  • Jun Yang Department of Anesthesiology, Huashan Hospital, Fudan University, Shanghai, China
  • Yifei Cheng Department of Anesthesiology, Huashan Hospital, Fudan University, Shanghai, China

DOI:

https://doi.org/10.17305/bb.2024.10443

Keywords:

Glioma, RANGAP1, TGF-β/Smad signaling pathway, SUMOylation, SUMO1

Abstract

Small Ubiquitin-like Modifier (SUMOylation) regulates a variety of cellular activities, and its dysregulation has been associated with glioma etiology. The aim of this research was to clarify the function of SUMOylation-related genes in glioma and determine relevant prognostic markers. The Cancer Genome Atlas (TCGA) Glioma and GSE16011 datasets were analyzed through bioinformatics to identify Ran GTPase activating protein 1 (RANGAP1) as the hub gene for further study. Experimental validation consisted of quantitative real-time polymerase chain reaction (qRT-PCR), western blotting (WB), and immunoprecipitation (IP) to evaluate RANGAP1 expression, function, and interaction with SUMO1. To assess the role of RANGAP1 knockdown and SUMOylation in glioma cells, various assays were conducted, including cell proliferation, migration, invasion, and apoptosis. In addition, cell cycle analysis and immunofluorescence were performed. Through bioinformatics, RANGAP1 was identified as a crucial prognostic gene for glioma. Experimental studies confirmed the downregulation of RANGAP1 in glioma cells and verified that RANGAP1 repair impedes tumor growth. When it comes to RANGAP1 silencing, it enhanced cell proliferation, invasion and migration. Additionally, SUMO1 was identified as a specific SUMO molecule coupled to RANGAP1, affecting the location of Sma and Mad related protein 4 (Smad4) in the nucleocytoplasm and the transforming growth factor (TGF)-β/Smad signaling pathway. The functional impact of RANGAP1 SUMOylation on cell proliferation and migration was further confirmed through experiments using a SUMOylation-impairing mutation (K524R). Our findings suggest that RANGAP1 may be a potential prognostic marker in gliomas and could play a role in regulating cell proliferation, migration, and invasion. SUMOylation of RANGAP1 is responsible for regulating the TGF-β/Smad signaling pathway, which is crucial for the progression of tumors. Further investigations and experiments are necessary to confirm these results.

Citations

Downloads

Download data is not yet available.
Impact of RANGAP1 SUMOylation on Smad4 nuclear export by bioinformatic analysis and cell assays

Downloads

Additional Files

Published

17-10-2024

Data Availability Statement

The data that support the findings of this study are available on request from the corresponding author upon reasonable request.

Issue

Section

Research article

Categories

How to Cite

1.
Impact of RANGAP1 SUMOylation on Smad4 nuclear export by bioinformatic analysis and cell assays. Biomol Biomed [Internet]. 2024 Oct. 17 [cited 2024 Dec. 4];24(6):1620–1636. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/10443